Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living
Go back to Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 156.27 +0.63 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $155.64 | 52 Week High | $58.46 | |||
| Open | $153.99 | 52 Week Low | $31.25 | |||
| Day High | $156.82 | P/E | N/A | |||
| Day Low | $151.77 | EPS | $-0.69 | |||
| Volume | 288,434 | |||||
